Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) https://validator.w3.org/feed/docs/rss2.html New Dual-Targeting Protein and Chemotherapy Boost T-Cell Attack on Lung Cancer Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) Registration Open: 1st International Scientific Symposium in Hematologic Malignancy (CETH, Chulalongkorn University) Khonkaen University Team Vaccine and Therapeutic RNA Research Forum 2025 University of Wisconsin School of Medicine and Public Health Chiang Mai University Team Antitumor activities of chimeric antigen receptor T cells targeting Mucin-1 with self-released anti-PD-1 IgG antibody A multi-center clinical research project to study the Safety and Efficacy of CD19 CAR T-cells in ALL (Acute Lymphoblastic Leukemia) by Academic Hubs Chulalongkorn University Team Mahidol University Team NRCT Hosts Seminar on “Thai Cancer Immunotherapy: Collaboration, Regulation, and the Future of Treatment” at MHESI Fair 2025 Antitumor activities of chimeric antigen receptor T cells targeting Mucin-1 with self-released anti-PD-1 IgG antibody Scientific Meeting: Medical Applications of Gene Editing and Synthetic Biology Technologies Efficiently targeting folate receptor alpha-positive ovarian cancer by human antibody VH domain-based chimeric antigen receptor (CAR) Enhancing T cell cytotoxicity against lung cancer with an αPD-L1 protein engager and gemcitabine combination therapy Enhancing T cell cytotoxicity in multiple myeloma with bispecific αPD-L1 × αCD3 T cell engager-armed T cells and low-dose bortezomib therapy New Immune Cell Engager Combined with Chemotherapy Boosts Attack on Multiple Myeloma Researchers Develop Method to Remove Specific Problematic Proteins for Improved Drug Effects Enhancing Innate and Adaptive Immunity to Combat Multiple Myeloma: Combined Use of Trispecific NK Cell Engagers (TriKEs) and Bispecific T-Cell Engagers (BiTEs) in Immunotherapy Equipment Celebrating Excellence in Immunotherapy: Dr. Piriya Luangwattananun Honored as Young Investigator Our Team Announcement: Student Progress Report 1/2025 TTCI Members Receive Research Recognition Awards from Faculty of Sciences, Chiang Mai University Special Lecture: Advanced Cellular Therapeutics for Hematologic Malignancies Chula Licenses Thai PD-1 Antibody to US Biopharma นวัตกรรมเซลล์บำบัดมะเร็ง “CAR-T cell” โอกาสใหม่ของผู้ป่วยมะเร็งไทย TTCI Welcomes World-Class Expert for Special Lecture and Advisory Role TTCI Representatives Join World Immunotherapy Council Asia Pacific (WIC APAC 2025) in Singapore TTCI Researchers Present and Collaborate at the 29th Annual Meeting of the Japanese Association of Cancer Immunology The TTCI team is thrilled to announce our participation in the AP-SciBio 2025 Development of CAR T-cell Products for the Treatment of Hematologic Malignancies to Enhance the Competitiveness of Thailand’s Advanced Therapy Medicinal Products (ATMP) Industry (Phase 1) Clinical research project on CAR T-cells in collaboration with a multi-institutional network (Academic CAR T-cell network). Safety/Phase I study of PiggyBac transposon mediated Chimeric Antigen Receptor T cells targeting CD-19 in Thai patients with refractory systemic lupus Erythematosus Expanding Horizons in Immunotherapy: Integrating Advanced Cell Engineering, Reprogramming, and Adjunct Therapies for Cancer and inflammatory-mediated diseases Prince of Songkla University Team Thai Study Links Diet, Gut Microbes, and Lung Cancer Immunotherapy Outcomes Houston Methodist Hospital and Neal Cancer Center QIMR Berghofer Medical Research Institute University of Pittsburgh Duke-NUS Medical School Teikyo University Shinshu University Shenzhen Geno-Immune Medical Institute University of Otago Nagoya Pediatrics Nagoya Medicine Kumamoto University University of Glasgow